Status:
UNKNOWN
Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies
Lead Sponsor:
Ospedale San Carlo Borromeo
Collaborating Sponsors:
Associazione Oncologica Milanese AmoLaVita ONLUS
Conditions:
Cognitive Impairment
Haematological Malignancy
Eligibility:
All Genders
70-90 years
Phase:
NA
Brief Summary
BACKGROUND Neurocognitive symptoms have a high prevalence in cancer patients, resulting in a significant impact on daily life and tolerance to therapy. It's estimated that about 30% of cancer patients...
Eligibility Criteria
Inclusion
- Ages ≥ 70 years;
- Signed Informed Consent Form;
- Haematological malignancy diagnosis that requires whithin three months a treatment.
Exclusion
- Inability (ex. severe visual and/or hearing impairments, lack of caregivers) to carry out the tests required by the study;
- Comorbidity or condition that, in the investigator's opinion, may compromise the safe execution of the tests.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04673305
Start Date
March 1 2021
End Date
September 1 2023
Last Update
December 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ASST SANTI PAOLO CARLO - SAN CARLO BORROMEO HOSPITAL - SSd. Onco - Haematology and SC Neurology
Milan, Italy, 20153